ES2721180T3 - Productos terapéuticos usando células adiposas y secreciones celulares - Google Patents

Productos terapéuticos usando células adiposas y secreciones celulares Download PDF

Info

Publication number
ES2721180T3
ES2721180T3 ES12833860T ES12833860T ES2721180T3 ES 2721180 T3 ES2721180 T3 ES 2721180T3 ES 12833860 T ES12833860 T ES 12833860T ES 12833860 T ES12833860 T ES 12833860T ES 2721180 T3 ES2721180 T3 ES 2721180T3
Authority
ES
Spain
Prior art keywords
cells
adipose tissue
composition
tissue derived
secretions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12833860T
Other languages
English (en)
Inventor
Graham Vesey
Rebecca Anne Webster
Richard Lilischkis
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cell Ideas Pty Ltd
Original Assignee
Cell Ideas Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2011903938A external-priority patent/AU2011903938A0/en
Application filed by Cell Ideas Pty Ltd filed Critical Cell Ideas Pty Ltd
Application granted granted Critical
Publication of ES2721180T3 publication Critical patent/ES2721180T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/35—Fat tissue; Adipocytes; Stromal cells; Connective tissues
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/02—Preservation of living parts
    • A01N1/0205—Chemical aspects
    • A01N1/021—Preservation or perfusion media, liquids, solids or gases used in the preservation of cells, tissue, organs or bodily fluids
    • A01N1/0221—Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0653—Adipocytes; Adipose tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dentistry (AREA)
  • Environmental Sciences (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)

Abstract

Una composición congelada que comprende células de la progenie de cultivo de células sometidas a múltiples pases de una suspensión de células derivadas de tejido adiposo y secreciones de células derivadas de tejido adiposo, en la que dichas secreciones comprenden medios clarificados y/o concentrados de cultivo de células derivadas de tejido adiposo que han surgido como células de la progenie o una línea celular de cultivo anterior para su uso en el tratamiento de una afección seleccionada del grupo que consiste en un trastorno inflamatorio, una lesión de ligamentos y una lesión de tendón, o alivio del dolor asociado con un trastorno inflamatorio, una lesión de ligamentos o una lesión de tendón, en un sujeto mamífero, en el que la composición se administra a un sujeto después de descongelar la composición.
ES12833860T 2011-09-23 2012-09-21 Productos terapéuticos usando células adiposas y secreciones celulares Active ES2721180T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
AU2011903938A AU2011903938A0 (en) 2011-09-23 Therapeutic methods and compositions
AU2012901350A AU2012901350A0 (en) 2012-04-04 Therapeutic methods and compositions
AU2012903646A AU2012903646A0 (en) 2012-08-23 Therapeutic methods and compositions
PCT/AU2012/001140 WO2013040649A1 (en) 2011-09-23 2012-09-21 Therapeutics using adipose cells and cell secretions

Publications (1)

Publication Number Publication Date
ES2721180T3 true ES2721180T3 (es) 2019-07-29

Family

ID=47913679

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12833860T Active ES2721180T3 (es) 2011-09-23 2012-09-21 Productos terapéuticos usando células adiposas y secreciones celulares
ES19153401T Active ES2880084T3 (es) 2011-09-23 2012-09-21 Terapias que usan células adiposas y secreciones celulares

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19153401T Active ES2880084T3 (es) 2011-09-23 2012-09-21 Terapias que usan células adiposas y secreciones celulares

Country Status (9)

Country Link
US (3) US10111909B2 (es)
EP (3) EP2744892B1 (es)
JP (5) JP6162123B2 (es)
AU (1) AU2012313352B2 (es)
CA (1) CA2885487C (es)
DK (2) DK3546569T3 (es)
ES (2) ES2721180T3 (es)
SG (2) SG10201606745XA (es)
WO (1) WO2013040649A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9192695B2 (en) 2008-11-20 2015-11-24 Allosource Allografts combined with tissue derived stem cells for bone healing
US20140286911A1 (en) 2013-03-15 2014-09-25 Allosource Cell repopulated collagen matrix for soft tissue repair and regeneration
SG10201606745XA (en) * 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions
JP2023002772A (ja) * 2011-09-23 2023-01-10 レジニアス リミテッド 脂肪細胞および細胞分泌物を使用する治療
AU2013204930C1 (en) * 2012-09-26 2015-01-22 Cell Ideas Pty Ltd Therapeutics using multiple injections of cells
WO2014078705A1 (en) 2012-11-15 2014-05-22 Allosource Minced cartilage systems and methods
NZ629700A (en) 2012-12-24 2017-01-27 Cell Ideas Pty Ltd Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
US9186253B2 (en) * 2013-02-22 2015-11-17 Allosource Cartilage mosaic compositions and methods
AU2014236705B2 (en) 2013-03-15 2018-04-12 Allosource Perforated osteochondral allograft compositions
CA2915249C (en) * 2013-06-19 2022-04-12 Spinalcyte, Llc Adipose cells for chondrocyte applications
CN106255884B (zh) * 2013-10-04 2019-01-11 赛尔爱迪尔私人有限公司 用于细胞治疗的生物标志物
WO2016094932A1 (en) 2014-12-19 2016-06-23 Cell Ideas Pty Ltd Improved cell therapies
AU2016321448B2 (en) 2015-09-08 2023-02-02 Cell Ideas Pty Ltd Cell expansion methods and therapeutic compositions
EP3381458B1 (en) * 2015-11-24 2023-06-07 Rohto Pharmaceutical Co., Ltd. Therapeutic agent for liver disease containing stromal cells derived from adipose tissue and method for producing the same
WO2018211498A1 (en) 2017-05-15 2018-11-22 Stem Cell Medicine Ltd. Treatment of multiple sclerosis with adipose-derived stem cells
AU2017414803A1 (en) 2017-05-15 2019-12-05 Mapi Pharma Ltd. Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells
KR20230117627A (ko) * 2017-10-02 2023-08-08 히로타로 후쿠오카 두피 혹은 피부의 개질, 창상 치유, 또는 모발의 개질에이용되기 위한 의약 조성물
AU2019287353A1 (en) * 2018-06-15 2021-02-04 NextPhase Therapeutics, Inc. Pharmaceutical composition for dermatology and uses thereof
JP7429032B2 (ja) * 2019-12-24 2024-02-07 学校法人順天堂 間質性肺炎モデル非ヒト動物の作製方法
JP6826744B1 (ja) * 2020-07-17 2021-02-10 医療法人Ｙａｎａｇａ ＣＬｉｎｉｃ 成熟脂肪細胞含有組成物の製造方法
CN114452303A (zh) * 2020-11-10 2022-05-10 上海萨美细胞技术有限公司 无细胞脂肪提取液对关节炎的治疗用途
IT202100003062A1 (it) * 2021-02-11 2022-08-11 Gaia Margiotta "processo di crioconservazione di tessuto adiposo"
CN115521908A (zh) * 2022-10-24 2022-12-27 潍坊天创生物科技有限公司 一种脂肪间充质干细胞的体外培养及外泌体的分离纯化方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037175A (en) 1996-03-12 2000-03-14 The University Of South Florida Method and media for enhancing cryopreservation of cells
US7078232B2 (en) * 1999-08-19 2006-07-18 Artecel, Inc. Adipose tissue-derived adult stem or stromal cells for the repair of articular cartilage fractures and uses thereof
US20030054331A1 (en) 2001-09-14 2003-03-20 Stemsource, Inc. Preservation of non embryonic cells from non hematopoietic tissues
JP2005508393A (ja) * 2001-11-09 2005-03-31 アーテセル・サイエンシズ・インコーポレーテツド 胚および成人幹細胞をサポートするための間質細胞の使用の方法および組成物
JP4653952B2 (ja) * 2001-12-07 2011-03-16 サイトリ セラピューティクス インコーポレイテッド 処理済み脂肪吸引細胞で患者を治療するためのシステムと方法
JP2007508018A (ja) 2003-10-08 2007-04-05 べト−ステム インコーポレイテッド 新規の幹細胞組成物の調製法および使用法、ならびにこの組成物を含有するキット
US8715733B2 (en) * 2004-07-23 2014-05-06 DePuy Synthes Products, LLC Enhanced adipose tissue
US20100092432A1 (en) 2006-08-08 2010-04-15 Takenori Ozaki Cell preparation containing multipotential stem cells originating in fat tissue
JP2010505849A (ja) * 2006-10-06 2010-02-25 ユニバーシティ オブ バージニア パテント ファウンデーション 糖尿病性創傷治癒に有用な方法および組成物
WO2009115581A2 (en) 2008-03-19 2009-09-24 Cryo-Save Ag Improved cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
US9144584B2 (en) 2008-06-11 2015-09-29 Cell4Vet Corporation Adipose tissue-derived stem cells for veterinary use
AU2009201915C1 (en) 2008-08-22 2015-02-26 Regeneus Ltd Therapeutic methods
KR101328604B1 (ko) * 2009-04-28 2013-11-11 (주)안트로젠 누공 치료를 위한 자가 및 동종의 지방 유래 스트로마 줄기세포 조성물
US20120201791A1 (en) 2009-10-15 2012-08-09 Tai June Yoo Methods of treating diseases or conditions using mesenchymal stem cells
EP2685993B9 (en) * 2011-03-15 2017-04-05 Cell Ideas Pty Ltd. Composition adipose tissue-derived secretions for use in the topical treatment or prevention of acne
SG10201606745XA (en) * 2011-09-23 2016-10-28 Cell Ideas Pty Ltd Therapeutics using adipose cells and cell secretions

Also Published As

Publication number Publication date
SG10201606745XA (en) 2016-10-28
JP6839038B2 (ja) 2021-03-03
US20200261510A1 (en) 2020-08-20
WO2013040649A1 (en) 2013-03-28
JP6162123B2 (ja) 2017-07-12
EP3546569A1 (en) 2019-10-02
US10660921B2 (en) 2020-05-26
ES2880084T3 (es) 2021-11-23
AU2012313352A1 (en) 2013-05-02
JP6912512B2 (ja) 2021-08-04
DK2744892T3 (en) 2019-04-23
DK3546569T3 (da) 2021-07-12
EP3546569B1 (en) 2021-06-16
JP2014527821A (ja) 2014-10-23
AU2012313352B2 (en) 2015-07-02
EP2744892B1 (en) 2019-03-20
CA2885487C (en) 2021-11-16
EP3868871A1 (en) 2021-08-25
JP2017193566A (ja) 2017-10-26
SG2014013676A (en) 2014-05-29
JP2019142971A (ja) 2019-08-29
US20190015455A1 (en) 2019-01-17
JP2022033865A (ja) 2022-03-02
JP2021155461A (ja) 2021-10-07
EP2744892A1 (en) 2014-06-25
CA2885487A1 (en) 2013-03-28
JP7022863B2 (ja) 2022-02-18
EP2744892A4 (en) 2015-05-20
US20140234272A1 (en) 2014-08-21
AU2012313352A9 (en) 2013-09-26
US10111909B2 (en) 2018-10-30

Similar Documents

Publication Publication Date Title
ES2721180T3 (es) Productos terapéuticos usando células adiposas y secreciones celulares
BR112014031874A2 (pt) método para preparar células-tronco em concentração elevada
BR112013004917A2 (pt) terapias de células tronco alogênicas sistêmicas para tratamento de doenças em animais.
CO7151524A2 (es) Anticuerpos antagonistas mejorados contra factor-8 de crecimiento y diferenciación y usos de los mismos
NZ603913A (en) Method of engrafting cells from solid tissues
BR112014015417A8 (pt) diferenciação de células-tronco embrionárias humanas em células positivas de insulina hormonal únicas
CL2015002725A1 (es) Compuestos aromáticos sustituidos para el tratamiento de la fibrosis pulmonar, la fibrosis hepática, la fibrosis de la piel y la fibrosis cardíaca
BR112013032659A2 (pt) método para o tratamento de células-tronco mesenquimais, que compreende a obtenção e o isolamento das células-tronco mesenquimais e a cultura das células em um meio de tratamento; células-tronco mesenquimais; e uso das células
ECSP13012869A (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos
EA201391154A3 (ru) Способы и композиции для нацеливания на адипоциты у млекопитающих
BRPI1013771A2 (pt) "células-tronco mesenquimais projetadas e método de uso das mesmas para tratar tumores."
JP2014527821A5 (es)
IN2015DN02729A (es)
BR112013004616A2 (pt) diferenciação das células tronco embrionárias humanas
MX2016005824A (es) Metodo de cultivo celular.
BR112017019189A2 (pt) agente terapêutico celular para tratamento de câncer e terapia de combinação com o mesmo
BR112018069090A2 (pt) tratamento de câncer com base na distribuição de oligos por meio de junções comunicantes a partir de células estaminais mesenquimatosas humanas (hmsc)
BR112015009229A2 (pt) composição tendo como alvo a expressão de genes para plaquetas, célula tronco hematopoiética, uso da referida célula tronco e método in vitro ou ex vivo para gerar uma célula tronco modificada
SG11201804755VA (en) Method for manufacturing tissue/organ by using blood cells
CL2015003402A1 (es) Células madres adultas adiposas, humanas, pluripotentes: aislamiento, caracterización e implicaciones clinicas
BR112015000547A2 (pt) métodos para tratar tecido; e composição de tecido
JP2018501241A5 (es)
UY34009A (es) ?uso de receptor de a2b adenosina para tratar la insuficiencia cardíaca y la arritmia en pacientes posinfarto de miocardio?.
BR112016028561A2 (pt) composição, forma de dosagem, e, métodos para reduzir o risco para mortalidade em um indivíduo, o risco para uma doença ou condição em um indivíduo, triglicerídeos em um sangue de indivíduo, a frequência cardíaca em repouso de um indivíduo, o colesterol de lipoproteína de densidade não alta em um indivíduo, o colesterol total em um indivíduo, a apolipoproteína b em um sangue de indivíduo, pressão sanguínea sistólica em um indivíduo e a pressão sanguínea diastólica em um indivíduo, para prolongar a vida de um indivíduo, para tratar hipertrigliceridemia em um indivíduo e para aumentar um índice de ômega-3 em células vermelhas do sangue de um indivíduo.
JP2012507997A5 (es)